IL17A and colitis: Alleviation of experimental colitis by enhancing intestinal barrier function through exosomal miR‐181a. Decreased expression of inflammatory cytokines in serum, including TNF‐α, IL‐6, IL‐1b, IL‐17 and IL‐18.